ChemoMetec A/S/DKr CHEMM
1D1W1MYTD1Y5YMAX
Capital at risk
About ChemoMetec A/S
ChemoMetec A/S is a biotechnology and life sciences company that specializes in the development, production, and sale of high-quality instruments for cell counting and analysis. Located in Denmark, the company serves various sectors, including research institutions, academic laboratories, and pharmaceutical companies. Its product portfolio includes advanced cell counters and analyzers, such as the NucleoCounter series, which are utilized for precise and reliable cell counting across multiple applications. Established in 1997, ChemoMetec has positioned itself through innovative technology that focuses on accuracy and ease of use. The company operates with a global reach, serving customers through both direct sales and a network of distributors.
- Ticker
- DKr CHEMM
- Sector
- Health
- Primary listing
- CSE
- Employees
- 172
- Headquarters
- Allerød, Denmark
- Website
- chemometec.com
ChemoMetec A/S Metrics
BasicAdvanced
kr 8.4B
41.12
kr 11.60
-
kr 7.00
1.47%
Price and volume
Market cap
kr 8.4B
52-week high
kr 804.00
52-week low
kr 235.20
Average daily volume
83K
Dividend rate
kr 7.00
Financial strength
Current ratio
4.092
Quick ratio
3.063
Long term debt to equity
0.003
Total debt to equity
0.006
Dividend payout ratio (TTM)
60.35%
Interest coverage (TTM)
640.29%
Profitability
EBITDA (TTM)
281.251
Gross margin (TTM)
95.10%
Net profit margin (TTM)
39.49%
Operating margin (TTM)
49.11%
Effective tax rate (TTM)
21.82%
Revenue per employee (TTM)
kr 2,970,000
Management effectiveness
Return on assets (TTM)
18.58%
Return on equity (TTM)
28.86%
Valuation
Price to earnings (TTM)
41.121
Price to revenue (TTM)
16.24
Price to book
11.58
Price to tangible book (TTM)
16.25
Price to free cash flow (TTM)
72.833
Free cash flow yield (TTM)
1.37%
Free cash flow per share (TTM)
6.549
Dividend yield (TTM)
1.47%
Forward dividend yield
1.47%
Growth
Revenue change (TTM)
3.12%
Earnings per share change (TTM)
8.31%
3-year revenue growth (CAGR)
4.77%
10-year revenue growth (CAGR)
19.62%
3-year earnings per share growth (CAGR)
4.15%
10-year earnings per share growth (CAGR)
33.02%
Bulls say / Bears say
ChemoMetec delivered 3% revenue growth and 9% EBITDA growth in 2025/26, lifting the EBITDA margin to 55% and net profit to DKK 201.8 million despite market uncertainty. Operating cash flow also remained strong at DKK 210.4 million. (rss.globenewswire.com) (ChemoMetec)
The XcytoMatic platform is gaining traction: annual sales rose from DKK 27.7 million to DKK 61.8 million, while Q3 XcytoMatic and NC-203 sales more than quadrupled excluding the accounting adjustment. This supports a shift toward higher-value automation and bioprocessing products. (rss.globenewswire.com) (ChemoMetec)
The Roche Diagnostics collaboration provides a credible commercialization and validation pathway for integrating ChemoMetec’s XM30 with Roche’s Cedex Bio Analyzer; management’s 2026/27 guidance also calls for revenue of DKK 545–575 million and EBITDA of DKK 300–315 million. (investor.chemometec.com) (ChemoMetec)
North America represented 54% of 2025/26 revenue, yet regional revenue fell 6% in DKK; in Q3, revenue was down 14% year over year after excluding the IFRS-related one-off, highlighting geographic and currency concentration risk. (rss.globenewswire.com) (ChemoMetec)
Consumables revenue declined 10% in Q3, with ChemoMetec citing fewer active clinical trials, fewer patients treated and major players withdrawing from the cell-and-gene-therapy market. This pressures the recurring-revenue component while newer instrument sales scale up. (investor.chemometec.com) (ChemoMetec)
The 2026/27 outlook implies relatively moderate growth of roughly 7–13% for both revenue and EBITDA, while management plans to propose no dividend for 2025/26 because of the share buyback programme, which may limit near-term income appeal. (rss.globenewswire.com) (ChemoMetec)
Data summarised monthly by Lightyear AI. Last updated on 11 Sept 2026.
Upcoming events
No upcoming events
Funds containing ChemoMetec A/S
AllUSDEURGBP
Fund name | Fund size | DKr CHEMM weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.13% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.13% |
iShares Healthcare Innovation£DRDR | £1B | 0.13% |
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.08% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.